CDK4/6 inhibitors in advanced breast cancer, what is beyond?

ABSTRACT: Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.

SUBMITTER: Mohammed AA 

PROVIDER: S-EPMC6683209 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature